Full Name
Dr. Francesco Passamonti MD
Job Title
Professor of Hematology
Company/Affiliation
University of Milan
Speaker Bio
Francesco Passamonti is a full Professor of Hematology at the University of Milano Statale, Milano, and Head of Hematology at the Policlinico di Milano, Ospedale Maggiore, Fondazione I.R.C.C.S. Ca’ Granda, Milano, Italy. He worked as a full Professor at the University of Insubria of Varese and Head of Hematology at the Varese Hospital in Italy from 2010 to 2023, and as an Assistant Professor of Hematology and Hematologist at the University of Pavia in Italy from 1998 to 2010.
He is principal investigator in many clinical trials in hematological malignancies; however, his main area of interest is in Philadelphia-negative myeloproliferative neoplasms (MPNs): polycythemia vera, essential thrombocythemia, and myelofibrosis. He collaborated on the definition of the molecular basis of MPNs and then designed new translational studies for their applications. He designed new prognostic models for essential thrombocythemia (IPSET), for primary (DIPSS) and post-PV and post-ET MF (MYSEC-PM), and for defining effective responses to ruxolitinib treatment in patients with MF (RR6). He leads many clinical trials on the development of targeted therapies in MPNs. He participated as a panelist in the definition of diagnostic criteria, response to treatments, and guidelines for informing treatment decisions in MPN. More recently, he led the Italian Project on COVID-19 in hematological malignancies.
He is a member of the Board of the International Working Group on Myeloproliferative Research and Treatment, as well as the European LeukemiaNet Work Package 9 for MPN and the MPN WP of GIMEMA. Francesco Passamonti is a member of several hematology societies and editorial boards and is an invited speaker at several international meetings. He has authored and coauthored more than 300 articles on MPNs.
He is principal investigator in many clinical trials in hematological malignancies; however, his main area of interest is in Philadelphia-negative myeloproliferative neoplasms (MPNs): polycythemia vera, essential thrombocythemia, and myelofibrosis. He collaborated on the definition of the molecular basis of MPNs and then designed new translational studies for their applications. He designed new prognostic models for essential thrombocythemia (IPSET), for primary (DIPSS) and post-PV and post-ET MF (MYSEC-PM), and for defining effective responses to ruxolitinib treatment in patients with MF (RR6). He leads many clinical trials on the development of targeted therapies in MPNs. He participated as a panelist in the definition of diagnostic criteria, response to treatments, and guidelines for informing treatment decisions in MPN. More recently, he led the Italian Project on COVID-19 in hematological malignancies.
He is a member of the Board of the International Working Group on Myeloproliferative Research and Treatment, as well as the European LeukemiaNet Work Package 9 for MPN and the MPN WP of GIMEMA. Francesco Passamonti is a member of several hematology societies and editorial boards and is an invited speaker at several international meetings. He has authored and coauthored more than 300 articles on MPNs.
Speaking At
